The Cannabist Company (CBST) Fair Value & Analysis
Healthcare · CA · Market cap C$17.5M
Fair value as of: Jun 23, 2026
From 2 valuation models · updated 7 days ago
Fair value updated Jun 23, 2026 — revised from C$2.37 to C$0.1000 (−95.8%) since Jun 18, 2026.
Price vs Fair Value (12 months)
12‑month range C$0.0300 – C$0.2050 · the C$0.0350 price screens below the C$0.1000 fair value. As of Jun 23, 2026.
✦ Find undervalued quality stocks — 35,000+ analysed Find stocks →Analysis
The Cannabist Company (CBST) currently trades at C$0.0350, while our model-based Fair Value estimate is C$0.1000 — implying the stock looks roughly 185.7% undervalued today. We read business quality at 91/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Over the trailing twelve months, The Cannabist Company generated revenue of C$350M at a net margin of -51.2%. Revenue declined 30.4% year over year. Net debt stands at C$445M. Fundamentals as of Jun 23, 2026
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jun 23, 2026. TTM = trailing twelve months.
About the company
The Cannabist Company Holdings Inc. cultivates, manufactures, and sells cannabis products and related services for the medical and adult-use markets in the United States and internationally. The company operates medical and/or adult use marijuana businesses and dispensaries. It also offers flowers, concentrates, edibles, oils and tablets, and accessories under the dreamt, Seed & Strain, Triple Seven, Hedy, gLeaf, Classix, Press, and Amber brands. In addition, the company provides management services to licensed entities. The company was formerly known as Columbia Care Inc. and changed its name to The Cannabist Company Holdings Inc. in September 2023. The Cannabist Company Holdings Inc. was founded in 2012 and is headquartered in Chelmsford, Massachusetts.
Revenue & earnings trend
FY2020 – FY2024 · reported fiscal years
The Cannabist Company reported revenue of C$459M in FY2024 versus C$189M in FY2020, a compound +24.8%/yr. Reported net income was −C$106M in FY2024.
Open the full interactive analysis →
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 23, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 600276 | ¥47.08 | ¥26.59 | -44% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,786 | ₹991.46 | -44% |
| Zoetis Inc Z1TS34 | R$24.45 | R$6.33 | -74% |
| Hansoh Pharmaceutical Group 3692 | HK$29.30 | HK$23.90 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,639 | ₹1,281 | -81% |
| Swedish Orphan Biovitrum AB SOBI | kr 446.60 | kr 234.19 | -48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is The Cannabist Company (CBST) undervalued?
What is the fair value of CBST?
What is the quality score of CBST?
What is the revenue of The Cannabist Company (CBST)?
What is the net profit margin of CBST?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.